US considers shortening marketing exclusivity to push forward USMCA

03-12-2019

Saman Javed

US considers shortening marketing exclusivity to push forward USMCA

Stuart Miles / Shutterstock.com

The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.


US Trump administration, US-Mexico-Canada, trade agreement, biologics, generics, cancer, arthritis, patents

LSIPR